Join
Live feed
·
PRReleasevia Quantisnow
Zenas BioPharma Inc. logo

Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine

ByQuantisnow·Wall Street's wire, on your screen.
ZBIO· Zenas BioPharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ZBIO (Zenas BioPharma Inc.) and more on Quantisnow.